

---

## **Recombinant human ErbB2 / Her2 protein, C-His-Avi (HEK293)**

Catalog Number: bs-47107P

Concentration: >0.5 mg/ml

AA Seq: 23-652/1255

Predicted MW: 72.3

Detected MW: Due to glycosylation, the protein migrates to 80-100 kDa based on Tris-Bis PAGE result.

Tags: C-His-Avi

Activity: Not tested

Endotoxin: <1.0 EU/μg as determined by LAL

Purity: >95% as determined by Tris-Bis PAGE; >95% as determined by SEC-HPLC

Purification: AC

Form: Lyophilized


Storage: Lyophilized from 0.22um filtered solution in PBS (pH7.4) with 5mM DTT. Normally 5% trehalose is added as protectant before Lyophilization.

Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.


**Background:** This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008].

### **VALIDATION IMAGES**


---




Recombinant Human ErbB2/Her2 Protein on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.



The purity of Recombinant Human ErbB2/Her2 Protein is greater than 95% as determined by SEC-HPLC.



Immobilized Human Her2,His Tag at 0.2 $\mu$ g/ml (100 $\mu$ l/Well). Dose response curve for Anti-Her2 Ab. Trastuzumab,with the EC50 of 17.4ng/ml determined by ELISA.



Immobilized Human Her2,His Tag at 0.2 $\mu$ g/ml (100 $\mu$ l/Well). Dose response curve for Anti-Her2 Ab. with the EC50 of 15.9ng/ml/15.0ng/ml/15.7ng/ml determined by ELISA.